Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
-
Shares outstanding
-
62,650,155
-
Total 13F shares
-
44,653,689
-
Share change
-
+966,973
-
Total reported value
-
$1,899,776,557
-
Put/Call ratio
-
54%
-
Price per share
-
$42.54
-
Number of holders
-
196
-
Value change
-
+$38,913,870
-
Number of buys
-
85
-
Number of sells
-
102
Institutional Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) as of Q4 2021
As of 31 Dec 2021,
Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) was held by
196 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
44,653,689 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, VANGUARD GROUP INC, Bellevue Group AG, BlackRock Inc., STATE STREET CORP, JPMORGAN CHASE & CO, PRICE T ROWE ASSOCIATES INC /MD/, CITADEL ADVISORS LLC, BOXER CAPITAL, LLC, and Artal Group S.A..
This page lists
197
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.